Colin B. O’Leary

Novel immune gene expression signature risk-stratifies Mantle Cell Lymphoma outcomes independent of TP53 status

Jean L. Koff, Veronica Russell, Rachel Kositsky, David L. Jaye et autres

Abstract Background: The prognostic impact of specific genomic changes in mantle cell lymphoma (MCL) is not well characterized beyond altered TP53, which is recognized as a high-risk marker and commonly assessed at diagnosis, and the “proliferation signature” developed using gene expression in …

us, gb, fi, dk, Afrique du Sud, hk, sg, ca, qa (code pays fourni par la source)

Racial differences in mycosis fungoides and Sézary syndrome: A multicenter cohort study

Pamela B. Allen, Subir Goyal, Swaminathan P. Iyer, Sai Talluru et autres

us (code pays fourni par la source)

PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy

Andrés Chang, Adam Pelletier, Donald J. McGuire, Maria Tsagiopoulou et autres

Chronic lymphocytic leukemia (CLL) remains incurable despite treatment advances, and a major challenge is that biomarkers that predict response and resistance to current therapies are lacking. We report that activated and proliferating malignant CLL B cells in circulation express PD-1, a protein …

us, gr (code pays fourni par la source)

Plasma Cytokine and Chemokine Profiles Predict Efficacy and Toxicity of Anti-CD19 CAR-T Cell Therapy in Large B-Cell Lymphoma

Fanyuan Zeng, Shuhua Wang, Tenzin Passang, Yiwen Li et autres

cn, us (code pays fourni par la source)

PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy

Andrés Chang, Adam Pelletier, Donald J. McGuire, Maria Tsagiopoulou et autres

Chronic lymphocytic leukemia (CLL) treatment has changed dramatically with the introduction of covalent Bruton's tyrosine kinase inhibitors (BTKi) and venetoclax, but biomarkers that predict response or early progression for these treatments are lacking. In our preliminary studies, we observed that some malignant …

us, gr (code pays fourni par la source)

Differential Antiviral IgG Titer Decay Rates after Frontline Chemoimmunotherapy in Patients with Aggressive B Cell Lymphoma

Andrés Chang, Alyssa Leal, Michael C. Churnetski, Lilin Lai et autres

Introduction Patients with B cell malignancies remain at high risk of morbidity and mortality from respiratory viruses like SARS-CoV-2. These patients often receive B cell-depleting agents in combination with chemotherapy as part of their cancer treatment, impairing their subsequent capacity to generate …

us (code pays fourni par la source)

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

James R. Cerhan, Matthew J. Maurer, Brian K. Link, Andrew L. Feldman et autres

To address the current and long-term unmet health needs of the growing population of non-Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/). A total of 7735 newly diagnosed patients aged 18 years and older …

us (code pays fourni par la source)

Use of an Integrated Functional Quantitation of Modulation of Transcriptional Pathways (IFQ) Assay in Untreated Mantle Cell Lymphoma Patients

Drew G. Gerber, Melanie Lopez-McDonald, Weiyuan Wang, Jean L. Koff et autres

Background: Mantle cell lymphoma (MCL) is an extremely heterogenous cancer, with substantial variation in clinical presentation and genetic makeup among individual patients. Chronic exposure to cytokines or inflammatory mediators is hypothesized to mediate pathogenesis and influence presentation in MCL, thus representing a …

us (code pays fourni par la source)

Early Plasma Levels of IL7 and IL15 Predict Response to Chimeric Antigen Receptor T Cell Therapy (CAR-T) in Large B-Cell Lymphoma (LBCL) Patients

Fanyuan Zeng, Hanwen Zhang, Shuhua Wang, Tenzin Passang et autres

Introduction Anti-CD19 chimeric antigen receptor T cells (CAR-T) have rapidly shifted the treatment paradigm for relapsed/refractory large B-cell lymphoma (LBCL) but produce durable complete response (CR) in only 30-40% of patients. In addition, CAR-T-mediated toxicities such as cytokine release syndrome (CRS) and …

us (code pays fourni par la source)

Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Single Center Retrospective Study

Tony Zhuang, Ashley A. McCook‐Veal, Jeffrey M. Switchenko, Tim Niyogusaba et autres

us (code pays fourni par la source)

Data from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies

Andrés Chang, Akil Akhtar, Lilin Lai, Victor M. Orellana‐Noia et autres

Patients with non–Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) elicit inadequate antibody responses after initial SARS-CoV-2 vaccination and remain at high risk of severe COVID-19 disease. We investigated IgG, IgA, and IgM responses after booster vaccination against recent SARS-CoV-2 variants including Omicron …

Data from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies

Andrés Chang, Akil Akhtar, Lilin Lai, Victor M. Orellana‐Noia et autres

Patients with non–Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) elicit inadequate antibody responses after initial SARS-CoV-2 vaccination and remain at high risk of severe COVID-19 disease. We investigated IgG, IgA, and IgM responses after booster vaccination against recent SARS-CoV-2 variants including Omicron …